The PharmaGEO Research Hub.

Nineteen field reports on Generative Engine Optimization (GEO), Answer Engine Optimization (AEO) and AI visibility for pharma brands. Anchored on the May 2026 PharmaGEO public index and primary research from Princeton, Ahrefs, IQVIA and the BMJ. Hard data on what ChatGPT, Claude, Gemini, Perplexity, Mistral and four more LLMs say about pharma brands across six engines, three languages and four therapeutic areas — and what brand, medical, regulatory and pharmacovigilance teams should do about it.

Get the Omnichannel Guide 2026 Get the GEO Playbook Browse articles
New · Free · 120 pages · PDF

The Omnichannel Pharma Guide 2026 edition.

The editorial counterpart to the PharmaGEO Playbook. 40 brands audited, 22 best practices, 22 anti-patterns, award-winning campaigns, HCP portals, patient communities, personas. Every asset read through the GEO and AI-visibility lens.

  • ✓The 2026 omnichannel landscape
  • ✓The GEO-Readiness framework, 6 dimensions
  • ✓40-brand audit, GEO scores by therapeutic area
  • ✓Top campaigns 2023–2026 + trends
  • ✓HCP content, social, patient personas
  • ✓Consultant's synthesis: Top 10 / Bottom 10 / Roadmap

Want a quick look first? Preview the first 20 pages →

No spam. We email the PDF link, you can opt out any time. See our privacy notice.

Doctrine companion · Free · PDF

The PharmaGEO Playbook 2026 edition.

The doctrine that pairs with the Omnichannel Guide. Eight doctrines, the search architecture LLMs reward, engine-by-engine guidance, and a 90-day mobilization plan, anchored on cross-engine and cross-language pharma data.

  • ✓State of GEO in pharma in 2026
  • ✓Recent sources prioritization trends
  • ✓Best practices for Pharma Brands
  • ✓GEO in MLR
  • ✓Owned vs Third party strategies

No spam. We email the PDF link, you can opt out any time. See our privacy notice.

All articles

Every article is built from real audit data, with citations to peer-reviewed sources where relevant.

Get the full playbook
No. 20 · ROI model

An ROI model for AI visibility in pharma.

A theoretical model applied to a $300M specialty brand. Every parameter is explicit and adjustable, and the break-even is the most informative number.

Read · 12 min
No. 18 · Comparison

PharmaGEO vs generic GEO tools.

Why pharma GEO is structurally different from B2C GEO, and how PharmaGEO compares with Profound, Evertune, Otterly, Peec.ai, Semrush, and Ahrefs.

Read · 8 min
No. 17 · Engines

There is no AI visibility. There are six.

The same brand can be #4 in OpenAI and #8 in Perplexity in the same week. A 33-point gap, decoded across four therapeutic areas.

Read · 11 min
No. 16 · Language

The language geography of AI visibility.

One molecule, three Answer Rates: 13.8% in English, 48.8% in French, 51.9% in Spanish. Why localization is not translation.

Read · 9 min
No. 15 · Sources

The citation source stack changes by therapeutic area.

NCCN ~85% in oncology. FDA labels lead in obesity. A specialist hub outranks NICE in psoriasis. There is no universal source playbook.

Read · 10 min
No. 14 · Metrics

Why answer rate and share of voice tell different stories.

A brand named in 93% of answers can hold only 22% of the conversation. The 4x compression every brand team should be measuring.

Read · 8 min
No. 13 · Mobilization

The 90-day pharma GEO mobilization plan.

Twelve weeks, three phases, named owners and KPI targets. The operating plan brand teams ship after the audit.

Read · 12 min
No. 12 · Pharmacovigilance

AI is already a pharmacovigilance surface.

FDA labels are the #1 and #2 cited sources in obesity prompts. Engines are already delivering boxed warnings — and surfacing T2D-only molecules on weight-loss queries.

Read · 10 min
No. 11 · Findings

8 key GEO findings every pharma brand needs.

Eight findings from the May 2026 PharmaGEO public index across obesity, lung cancer, atopic dermatitis, and psoriasis.

Read · 10 min
No. 10 · Benchmark

Benchmarking pharma brands across three engines.

A public-data benchmark across OpenAI, Perplexity, and Gemini in four therapeutic areas. Same brand, three rankings.

Read · 13 min
No. 09 · Optimize

The owned content playbook for the AI answer layer.

Eight tactics anchored on Princeton GEO research, Ahrefs brand-mention correlations, and the public PharmaGEO source data.

Read · 12 min
No. 08 · Methodology

How LLMs cite pharma sources, decoded.

Four source archetypes, four therapeutic areas, and the propagation chain that decides which domain wins citations.

Read · 12 min
No. 07 · Behavior

How HCPs are using AI search in 2026.

54% of HCPs use generative AI in clinical contexts (IQVIA). OpenEvidence hit one million consultations in a single day. What HCPs ask, and what they see.

Read · 9 min
No. 06 · Metrics

Measuring share of voice in LLM answers.

The 6-axis PharmaGEO score, sampling design, and the cadence that absorbs 59% monthly citation volatility.

Read · 9 min
No. 05 · Content

Medical writing built for AI retrieval.

The Princeton GEO results table, the 44.2% front-loading rule, and a before/after rewrite MLR can sign off on.

Read · 9 min
No. 04 · Competitive

Competitive blindspots in LLM pharma answers.

Your 2024 SEO competitive map is wrong twice over. A 7-row blindspot audit table, anchored on cross-engine and cross-language data.

Read · 11 min
No. 03 · Regulatory

MLR, EFPIA, and the AI answer layer.

The compliance frame for the AI surface — EPAR mirroring, off-label exposure, and an MLR-friendly content audit checklist.

Read · 12 min
No. 02 · Pattern

What the obesity TA tells us about GLP-1 launches in AI.

53.9% Top-3 SOV. FDA labels at #1 and #2 in citations. Off-label leakage. The structural pattern of every GLP-1 launch in the AI answer layer.

Read · 10 min
No. 01 · Primer

Why pharma needs GEO in 2026.

The state of AI search in pharma — anchored on IQVIA, CMI, and the public PharmaGEO index. The case for moving now.

Read · 8 min

Start with a free report.

Request a sample report Book a demo